The National Medical Products Administration (NMPA) issued the 103rd batch of reference listed drugs (RLDs) for generic drugs on April 4, 2026, including additions such as Zelucobren Sodium Injection. This update provides a legal benchmark for domestic companies engaged in high-end generic drug R&D and international registration. For overseas importers and distributors, the clarified RLDs indicate that subsequent generic drug applications in China will have higher compliance certainty and delivery stability when entering markets like the EU, Africa, and ASEAN under WHO PQ, EDQM, or FDA ANDA reviews.

Event Overview

On April 4, 2026, the NMPA officially released the 103rd batch of RLDs for generic drugs, adding new varieties like Zelucobren Sodium Injection. The directory serves as a regulatory reference for domestic generic drug development and international market access.

Impact on Sub-sectors

Domestic Generic Drug Manufacturers

The updated RLDs provide clearer regulatory guidance for high-end generic drug development, reducing formulation and clinical trial uncertainties. Manufacturers should align their R&D processes with the listed reference drugs to accelerate approvals.

Overseas Importers & Distributors

With standardized RLDs, Chinese generic drugs will face fewer regulatory hurdles in international markets. Importers should monitor subsequent batches for potential supply chain optimizations in target regions like the EU and ASEAN.

Contract Research Organizations (CROs)

CROs supporting bioequivalence studies may see increased demand as manufacturers adjust formulations to match the new RLDs. Proactive engagement with clients on updated testing protocols is advised.

Key Considerations for Stakeholders

Monitor Subsequent Batch Updates

Enterprises should track NMPA's quarterly RLD releases to identify emerging opportunities in niche therapeutic categories.

Prioritize High-Value Markets

For exporters, focus on markets where China's generic approvals demonstrate strong WHO PQ/EDQM alignment, such as Africa's Prequalification Program.

Supply Chain Preparations

Distributors should verify API sourcing strategies against the new RLDs to prevent formulation mismatches during regulatory inspections.

Editorial Perspective

From an industry standpoint, this update signals China's continued integration into global generic drug regulatory frameworks. While not an immediate market disruptor, the incremental alignment with international standards enhances long-term export competitiveness. Stakeholders should treat this as part of an ongoing standardization trend rather than a one-time policy shift.

Conclusion

The 103rd RLD batch reinforces China's systematic approach to generic drug regulation. For global partners, it represents a measurable step toward supply chain predictability. Current indications suggest steady progress rather than abrupt transformation, warranting calibrated business responses.

Source

National Medical Products Administration (NMPA) official announcement, April 4, 2026. Further updates expected through quarterly releases.